TrialBridgeNCT07907211
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Recruiting · Phase 4 · Chen Lijuan · registry updated 2026-10-30
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy. The main questions it aims to answer are: Does rivaroxaban reduce the incidence of venous thromboembolism (VTE) compared with aspirin in this patient population? What are the comparative safety profiles (particularly regarding bleeding events) of aspirin and rivaroxaban in this setting?
Inclusion
- Age 18 to 70 years at the time of screening.
- Newly diagnosed multiple myeloma with measurable disease according to the Chinese Guidelines for the Diagnosis and Management of Multiple Myeloma (2020 revision).
- Scheduled to receive immunomodulatory drug (thalidomide, lenalidomide, or pomalidomide)-based chemotherapy regimens.
- No clinical history or imaging evidence of venous thromboembolism at the time of initial diagnosis.
- Life expectancy \> 3 months.
- Adequate renal function defined as an endogenous creatinine clearance (CrCl) ≥30mL/min calculated by the Cockcroft-Gault formula.
Exclusion
- Active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, or other known acquired/congenital immunodeficiency syndromes.
- Baseline peripheral neuropathy or neuropathic pain ≥ Grade 2 according to NCI CTCAE version 5.0.
- Diagnosis of plasma cell leukemia.
- History of severe or recurrent venous/arterial thromboembolism prior to study enrollment.
- History of clinically significant or severe bleeding manifestations within 6 months prior to enrollment.
- Clinically significant or unstable cardiovascular diseases, including: